<DOC>
	<DOCNO>NCT01614769</DOCNO>
	<brief_summary>This study aim assess glimepiride affect recovery hypoglycemia participant type 2 diabetes mellitus . The primary objective estimate time take participant recover hypoglycemia euglycemia treatment either 2 mg 4 mg glimepiride compare placebo .</brief_summary>
	<brief_title>Effects Glimepiride Recovery From Hypoglycemia Participants With Type 2 Diabetes Mellitus ( MK-0000-253 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Has clinically confirm diagnosis type 2 diabetes mellitus ( T2DM ) control diet exercise alone , treat metformin dose &gt; = 12 week prior screen visit . Females reproductive potential demonstrate nongravid state , agree use ( and/or partner use ) two acceptable method birth control start least two week prior study , throughout study , least two week last dose study drug . Females nonreproductive potential , post menopausal , status post hysterectomy , oophorectomy tubal ligation . Is good health , T2DM . Has nonsmoker and/or non user nicotinecontaining product previous 6 month . If discontinue use previous 3 month , may enrol investigator 's discretion . Will follow American Heart Association weight maintain diet exercise program equivalent begin 2 week prior study poststudy visit . At screen visit Body Mass Index ( BMI ) = &lt; 40 kg/m^2 . At screen visit Hemoglobin A1c ( HbA1c ) &gt; = 7 % &lt; 10 % ( +/ 0.1 % ) . On morning randomization predose fast plasma glucose ( FPG ) &gt; = 126 mg/dL , = &lt; 250 mg/dL . Has history stroke , chronic seizure , major neurological disorder . Has history illness might confound result study pose additional risk participant . Has history type 1 diabetes mellitus , ketoacidosis , Cpeptide = &lt; 0.8 ng/mL , secondary form diabetes diabetic complication . Has history neoplastic disease . Is nurse mother . Has treat = &lt; one year screen visit sulfonylurea agent , meglitinides , dipeptidyl peptidase4 ( DPP4 ) inhibitor , glucagonlike peptide1 ( GLP1 ) analog , insulin . Has receive treatment within = &lt; 12 week screen visit peroxisome proliferatoractivated receptor γ ( PPARγ ) agonist . Is take medication comorbid condition anticipates take new medication begin 2 week prior study . Consumes excessive amount alcohol caffeinated beverage . Is regular user illicit drug , history drug abuse within previous 6 month . Has major surgery , lose 500 mL blood , participate another investigational study within 4 week prior screen visit . Is weight loss program , maintenance phase , treat weight loss medication within 8 week prestudy visit . Has history severe allergy , anaphylactic reaction intolerability drug , food , insulin , glimepiride sulfonamide derivative .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>